FDA grants approval status for Leucovorin Calcium ANDA072736
The FDA has granted an approval status (AP) for the ANDA072736 application for Leucovorin Calcium submitted by Hikma.
Company
Hikma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Hikma's ANDA072736 for Leucovorin Calcium is significant as it strengthens Hikma's position in the oncology supportive care market. This development may influence competitive dynamics and pricing strategies among generic manufacturers.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further developments regarding the launch timeline and market entry of Hikma's Leucovorin Calcium.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.